1. GPCR/G Protein
  2. Prostaglandin Receptor

Bimatoprost (Synonyms: AGN 192024)

Cat. No.: HY-B0191 Purity: 96.97%
Data Sheet SDS Handling Instructions

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

For research use only. We do not sell to patients.
Bimatoprost Chemical Structure

Bimatoprost Chemical Structure

CAS No. : 155206-00-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $165 In-stock
1 mg $50 In-stock
5 mg $180 In-stock
10 mg $280 In-stock
50 mg $800 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Target: Prostaglandin Receptor Bimatoprost is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. In December 2008, the indication to lengthen eyelashes was approved by the U.S. Food and Drug Administration (FDA); the cosmetic formulation of bimatoprost is sold as Latisse. In 2008-2011, at least three case series suggested that bimatoprost has the ability to reduce adipose (fat) tissue. Bimatoprost activates prostamide alpha F2 receptors found in the hair follicle to stimulate its growth rate. Research led by Professor Randall and the University of Bradford found that it may also offer a treatment for scalp hair regrowth in trials conducted on samples taken from men undergoing hair transplants. According to Allergan's package labeling, users of its Latisse cosmetic product didn't develop darker irises in clinical studies; however, "patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent."

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01387906 Kenneth Beer|Allergan|Beer, Kenneth R., M.D., PA Hypotrichosis March 2011 Phase 4
NCT00773136 University of Miami Hypertrichosis February 2008
NCT01271686 University of California, San Diego Intraocular Pressure|Glaucoma|Ocular Hypertension January 2011 Phase 4
NCT02444767 ForSight Vision5, Inc. Healthy Volunteers March 2015 Phase 1
NCT02830776 Tulane University|Allergan Dermatochalasis November 2016 Early Phase 1
NCT01391273 Allergan Eyelash Hypotrichosis July 2011 Phase 3
NCT01391286 Allergan Eyelash Hypotrichosis July 2011 Phase 3
NCT00187577 University of California, San Francisco Alopecia Areata June 2005
NCT02537015 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension August 2015 Phase 1|Phase 2
NCT02676310 Allergan Alopecia|Alopecia, Androgenetic|Baldness March 2016 Phase 1
NCT01200251 Duke University Madarosis|Hypotrichosis February 2007 Phase 3
NCT01298700 Allergan Glaucoma|Ocular Hypertension April 2011 Phase 4
NCT01623479 Allergan Eyelash Hypotrichosis November 2010
NCT01646151 Allergan Glaucoma, Open-Angle|Ocular Hypertension May 2012
NCT02061683 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2010 Phase 4
NCT00567788 Singapore National Eye Centre|Allergan Glaucoma, Angle-Closure July 2006
NCT02020512 Allergan Glaucoma, Open-Angle|Ocular Hypertension July 2011 Phase 4
NCT02170662 Duke University Male Pattern Hair Loss|Androgenetic Alopecia November 2009 Phase 2
NCT01830140 Allergan Glaucoma|Ocular Hypertension July 2013 Phase 3
NCT00941096 Larissa University Hospital Glaucoma|Ocular Hypertension July 2009 Phase 4
NCT00999557 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Alopecia|Breast Cancer January 2016
NCT01833741 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension December 2009 Phase 4
NCT01202513 Gian Sagar Medical College and Hospital Vitiligo|Repigmentation August 2010 Phase 4
NCT00705757 Summa Health System Glaucoma|Application Site Pigmentation Changes March 2008 Phase 4
NCT01361841 Centre de recherche du Centre hospitalier universitaire de Sherbrooke Ocular Hypertension|Primary Glaucoma January 2009
NCT00355446 Indiana University School of Medicine|Indiana University Cataract July 2001 Phase 4
NCT01229423 Allergan Eyelash Hypotrichosis November 2009 Phase 4
NCT02358369 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension January 2015 Phase 2
NCT01464424 Alcon Research Glaucoma|Ocular Hypertension|Open-Angle Glaucoma October 2011 Phase 4
NCT02848300 Allergan Androgenetic Alopecia July 2016 Phase 1
NCT02636946 Allergan Glaucoma|Open-Angle Ocular Hypertension February 2016 Phase 3
NCT01814761 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension May 2013 Phase 4
NCT02507687 Allergan Glaucoma, Open-Angle|Ocular Hypertension August 2015 Phase 3
NCT01189279 Allergan Alopecia|Alopecia, Androgenetic|Baldness October 2010 Phase 1
NCT00486486 Aristotle University Of Thessaloniki Glaucoma March 2007 Phase 4
NCT00847483 Pfizer Glaucoma|Ocular Hypertension January 2002 Phase 4
NCT01975714 Association for Innovation and Biomedical Research on Light and Image|European Vision Institute Clinical Research Network Glaucoma|Ocular Hypertension October 2013 Phase 4
NCT01099774 Allergan Glaucoma|Ocular Hypertension May 2010 Phase 3
NCT01448525 Allergan Hypotrichosis October 2011 Phase 4
NCT01589510 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2012
NCT00907426 Allergan Hypotrichosis August 2009 Phase 3
NCT01068964 Allergan Open-angle Glaucoma|Ocular Hypertension February 2010
NCT02505776 Allergan Eyelash Hypotrichosis December 2014
NCT01765764 Allergan Eyebrow Hypotrichosis March 2013 Phase 3
NCT01448837 Aristotle University Of Thessaloniki Glaucoma April 2010 Phase 4
NCT01698554 Allergan Idiopathic Eyelash Hypotrichosis November 2012 Phase 3
NCT01664039 Alcon Research Glaucoma|Ocular Hypertension September 2012 Phase 4
NCT01594970 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2012 Phase 4
NCT01489670 Allergan Glaucoma, Open-Angle|Ocular Hypertension September 2011
NCT02250651 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 16, 2014 Phase 3
NCT02247804 Allergan Glaucoma, Open-Angle|Ocular Hypertension October 23, 2014 Phase 3
NCT01064882 Allergan Eyelash Hypotrichosis March 2010 Phase 2
NCT00958035 Allergan Hypotrichosis November 2009 Phase 4
NCT01568008 Allergan Open-Angle Glaucoma|Ocular Hypertension October 2011
NCT00348062 Innovative Medical Glaucoma Phase 4
NCT00651859 Allergan Glaucoma|Ocular Hypertension November 2002 Phase 2
NCT02154217 University of Milan Glaucoma Phase 3
NCT01177098 Allergan Glaucoma|Ocular Hypertension October 2010 Phase 3
NCT02471105 Universitaire Ziekenhuizen Leuven|Allergan Ocular Hypertension|Glaucoma September 2015 Phase 4
NCT01915940 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension October 2013 Phase 2
NCT00347841 Innovative Medical Glaucoma Phase 4
NCT01853085 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension April 2013 Phase 4
NCT00347802 Innovative Medical Glaucoma Phase 4
NCT01291108 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2011 Phase 2
NCT01170884 Allergan Glaucoma|Ocular Hypertension December 2009 Phase 4
NCT01628588 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2010
NCT01632423 Allergan Glaucoma, Open-Angle|Ocular Hypertension February 2010
NCT00348023 Innovative Medical Glaucoma Phase 4
NCT00541242 Allergan Ocular Hypertension|Glaucoma December 2007 Phase 4
NCT00693420 Allergan Eyelashes April 2007 Phase 3
NCT01863953 Allergan Glaucoma|Ocular Hypertension June 2013 Phase 2
NCT02059655 Cardiff University|National Institute for Social Care and Health Research Graves' Ophthalmopathy November 2014 Phase 4
NCT01976624 Allergan Glaucoma, Open-Angle|Ocular Hypertension August 2009
NCT01023841 Allergan Eyelash Hypotrichosis|Alopecia Areata June 2010 Phase 4
NCT02742649 ForSight Vision5, Inc. Open-Angle Glaucoma|Ocular Hypertension March 2016 Phase 1|Phase 2
NCT02155049 Rabin Medical Center Thyroid Associated Ophthalmopathies November 2014 Phase 3
NCT02448043 Northwestern University|Allergan Nail Growth Cessation|Intraocular Pressure May 2015
NCT02571712 Allergan Glaucoma, Open-Angle|Ocular Hypertension November 15, 2015 Phase 4
NCT01426113 Allergan Glaucoma September 2011 Phase 3
NCT01243567 Allergan Glaucoma, Open-Angle June 2010 Phase 4
NCT00440011 Allergan Glaucoma|Ocular Hypertension August 2006 Phase 4
NCT01001195 Allergan Glaucoma, Open-Angle|Ocular Hypertension November 2009 Phase 2
NCT01216943 Allergan Glaucoma|Ocular Hypertension November 2010 Phase 3
NCT02097719 Allergan Glaucoma|Ocular Hypertension May 2014 Phase 4
NCT01904721 Allergan Alopecia|Alopecia, Androgenetic|Baldness August 2013 Phase 2
NCT01881126 Allergan Glaucoma|Ocular Hypertension June 2013 Phase 4
NCT00652496 Allergan Glaucoma|Ocular Hypertension January 2005 Phase 2
NCT00300443 Allergan Ocular Hypertension December 2005 Phase 2|Phase 3
NCT01547598 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 2011 Phase 4
NCT01525173 Allergan Glaucoma|Ocular Hypertension January 2012 Phase 4
NCT00716742 Allergan Open-Angle Glaucoma|Ocular Hypertension September 2004
NCT00538304 Allergan Glaucoma|Ocular Hypertension November 2007 Phase 2
NCT01110499 Allergan Ocular Hypertension|Primary Open-Angle Glaucoma June 2010 Phase 2
NCT00332540 Allergan Ocular Hypertension August 2001 Phase 3
NCT00332059 Allergan Ocular Hypertension May 2003 Phase 3
NCT00332072 Allergan Ocular Hypertension August 2001 Phase 3
NCT02143843 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension May 2014 Phase 1|Phase 2
NCT01157364 Allergan Open-Angle Glaucoma|Ocular Hypertension August 2010 Phase 1|Phase 2
NCT01628601 Allergan Glaucoma, Open-Angle|Ocular Hypertension May 2010
NCT01999348 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension November 2013
NCT02176356 Allergan Facial Rhytides|Crow's Feet Lines|Glabellar Lines|Nasolabial Fold June 2014 Phase 4
NCT01325337 Allergan Alopecia|Alopecia, Androgenetic|Baldness June 2011 Phase 2
NCT01325350 Allergan Alopecia|Baldness June 2011 Phase 2
NCT01253902 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 2010 Phase 4
NCT02863705 Allergan Glaucoma, Open-Angle|Normal Tension Glaucoma July 5, 2016 Phase 4
NCT00273455 Pharmaceutical Research Network Open-Angle Glaucoma January 2006 Phase 4
NCT00809848 Allergan Ocular Hypertension|Glaucoma February 2009 Phase 1|Phase 2
NCT00539526 Allergan Open Angle Glaucoma|Ocular Hypertension September 2007 Phase 4
NCT01016691 Vistakon Pharmaceuticals Open-angle Glaucoma|Ocular Hypertension October 2009 Phase 2
NCT01241240 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2011 Phase 3
NCT01217606 Allergan Glaucoma, Open-Angle|Ocular Hypertension January 2011 Phase 3
NCT01978015 University of Campinas, Brazil Uveitis, Anterior|Cystoid Macular Edema October 2011 Phase 4
NCT00329095 Robin, Alan L., M.D. Glaucoma|Ocular Hypertension December 2005 Phase 4
NCT01655758 University of Parma Ocular Hypertension January 2002 Phase 4
NCT02390284 University of Miami|National Eye Institute (NEI) Glaucoma September 2014 Phase 3
NCT01387906 Kenneth Beer|Allergan|Beer, Kenneth R., M.D., PA Hypotrichosis March 2011 Phase 4
NCT00773136 University of Miami Hypertrichosis February 2008
NCT01271686 University of California, San Diego Intraocular Pressure|Glaucoma|Ocular Hypertension January 2011 Phase 4
NCT02444767 ForSight Vision5, Inc. Healthy Volunteers March 2015 Phase 1
NCT02830776 Tulane University|Allergan Dermatochalasis November 2016 Early Phase 1
NCT01391273 Allergan Eyelash Hypotrichosis July 2011 Phase 3
NCT01391286 Allergan Eyelash Hypotrichosis July 2011 Phase 3
NCT00187577 University of California, San Francisco Alopecia Areata June 2005
NCT02537015 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension August 2015 Phase 1|Phase 2
NCT02676310 Allergan Alopecia|Alopecia, Androgenetic|Baldness March 2016 Phase 1
NCT01200251 Duke University Madarosis|Hypotrichosis February 2007 Phase 3
NCT01298700 Allergan Glaucoma|Ocular Hypertension April 2011 Phase 4
NCT01623479 Allergan Eyelash Hypotrichosis November 2010
NCT01646151 Allergan Glaucoma, Open-Angle|Ocular Hypertension May 2012
NCT02061683 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2010 Phase 4
NCT00567788 Singapore National Eye Centre|Allergan Glaucoma, Angle-Closure July 2006
NCT02020512 Allergan Glaucoma, Open-Angle|Ocular Hypertension July 2011 Phase 4
NCT02170662 Duke University Male Pattern Hair Loss|Androgenetic Alopecia November 2009 Phase 2
NCT01830140 Allergan Glaucoma|Ocular Hypertension July 2013 Phase 3
NCT00941096 Larissa University Hospital Glaucoma|Ocular Hypertension July 2009 Phase 4
NCT00999557 Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Alopecia|Breast Cancer January 2016
NCT01833741 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension December 2009 Phase 4
NCT01202513 Gian Sagar Medical College and Hospital Vitiligo|Repigmentation August 2010 Phase 4
NCT00705757 Summa Health System Glaucoma|Application Site Pigmentation Changes March 2008 Phase 4
NCT01361841 Centre de recherche du Centre hospitalier universitaire de Sherbrooke Ocular Hypertension|Primary Glaucoma January 2009
NCT00355446 Indiana University School of Medicine|Indiana University Cataract July 2001 Phase 4
NCT01229423 Allergan Eyelash Hypotrichosis November 2009 Phase 4
NCT02358369 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension January 2015 Phase 2
NCT01464424 Alcon Research Glaucoma|Ocular Hypertension|Open-Angle Glaucoma October 2011 Phase 4
NCT02848300 Allergan Androgenetic Alopecia July 2016 Phase 1
NCT02636946 Allergan Glaucoma|Open-Angle Ocular Hypertension February 2016 Phase 3
NCT01814761 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension May 2013 Phase 4
NCT02507687 Allergan Glaucoma, Open-Angle|Ocular Hypertension August 2015 Phase 3
NCT01189279 Allergan Alopecia|Alopecia, Androgenetic|Baldness October 2010 Phase 1
NCT00486486 Aristotle University Of Thessaloniki Glaucoma March 2007 Phase 4
NCT00847483 Pfizer Glaucoma|Ocular Hypertension January 2002 Phase 4
NCT01975714 Association for Innovation and Biomedical Research on Light and Image|European Vision Institute Clinical Research Network Glaucoma|Ocular Hypertension October 2013 Phase 4
NCT01099774 Allergan Glaucoma|Ocular Hypertension May 2010 Phase 3
NCT01448525 Allergan Hypotrichosis October 2011 Phase 4
NCT01589510 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2012
NCT00907426 Allergan Hypotrichosis August 2009 Phase 3
NCT01068964 Allergan Open-angle Glaucoma|Ocular Hypertension February 2010
NCT02505776 Allergan Eyelash Hypotrichosis December 2014
NCT01765764 Allergan Eyebrow Hypotrichosis March 2013 Phase 3
NCT01448837 Aristotle University Of Thessaloniki Glaucoma April 2010 Phase 4
NCT01698554 Allergan Idiopathic Eyelash Hypotrichosis November 2012 Phase 3
NCT01664039 Alcon Research Glaucoma|Ocular Hypertension September 2012 Phase 4
NCT01594970 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2012 Phase 4
NCT01489670 Allergan Glaucoma, Open-Angle|Ocular Hypertension September 2011
NCT02250651 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 16, 2014 Phase 3
NCT02247804 Allergan Glaucoma, Open-Angle|Ocular Hypertension October 23, 2014 Phase 3
NCT01064882 Allergan Eyelash Hypotrichosis March 2010 Phase 2
NCT00958035 Allergan Hypotrichosis November 2009 Phase 4
NCT01568008 Allergan Open-Angle Glaucoma|Ocular Hypertension October 2011
NCT00348062 Innovative Medical Glaucoma Phase 4
NCT00651859 Allergan Glaucoma|Ocular Hypertension November 2002 Phase 2
NCT02154217 University of Milan Glaucoma Phase 3
NCT01177098 Allergan Glaucoma|Ocular Hypertension October 2010 Phase 3
NCT02471105 Universitaire Ziekenhuizen Leuven|Allergan Ocular Hypertension|Glaucoma September 2015 Phase 4
NCT01915940 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension October 2013 Phase 2
NCT00347841 Innovative Medical Glaucoma Phase 4
NCT01853085 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension April 2013 Phase 4
NCT00347802 Innovative Medical Glaucoma Phase 4
NCT01291108 Allergan Glaucoma, Open-Angle|Ocular Hypertension April 2011 Phase 2
NCT01170884 Allergan Glaucoma|Ocular Hypertension December 2009 Phase 4
NCT01628588 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2010
NCT01632423 Allergan Glaucoma, Open-Angle|Ocular Hypertension February 2010
NCT00348023 Innovative Medical Glaucoma Phase 4
NCT00541242 Allergan Ocular Hypertension|Glaucoma December 2007 Phase 4
NCT00693420 Allergan Eyelashes April 2007 Phase 3
NCT01863953 Allergan Glaucoma|Ocular Hypertension June 2013 Phase 2
NCT02059655 Cardiff University|National Institute for Social Care and Health Research Graves' Ophthalmopathy November 2014 Phase 4
NCT01976624 Allergan Glaucoma, Open-Angle|Ocular Hypertension August 2009
NCT01023841 Allergan Eyelash Hypotrichosis|Alopecia Areata June 2010 Phase 4
NCT02742649 ForSight Vision5, Inc. Open-Angle Glaucoma|Ocular Hypertension March 2016 Phase 1|Phase 2
NCT02155049 Rabin Medical Center Thyroid Associated Ophthalmopathies November 2014 Phase 3
NCT02448043 Northwestern University|Allergan Nail Growth Cessation|Intraocular Pressure May 2015
NCT02571712 Allergan Glaucoma, Open-Angle|Ocular Hypertension November 15, 2015 Phase 4
NCT01426113 Allergan Glaucoma September 2011 Phase 3
NCT01243567 Allergan Glaucoma, Open-Angle June 2010 Phase 4
NCT00440011 Allergan Glaucoma|Ocular Hypertension August 2006 Phase 4
NCT01001195 Allergan Glaucoma, Open-Angle|Ocular Hypertension November 2009 Phase 2
NCT01216943 Allergan Glaucoma|Ocular Hypertension November 2010 Phase 3
NCT02097719 Allergan Glaucoma|Ocular Hypertension May 2014 Phase 4
NCT01904721 Allergan Alopecia|Alopecia, Androgenetic|Baldness August 2013 Phase 2
NCT01881126 Allergan Glaucoma|Ocular Hypertension June 2013 Phase 4
NCT00652496 Allergan Glaucoma|Ocular Hypertension January 2005 Phase 2
NCT00300443 Allergan Ocular Hypertension December 2005 Phase 2|Phase 3
NCT01547598 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 2011 Phase 4
NCT01525173 Allergan Glaucoma|Ocular Hypertension January 2012 Phase 4
NCT00716742 Allergan Open-Angle Glaucoma|Ocular Hypertension September 2004
NCT00538304 Allergan Glaucoma|Ocular Hypertension November 2007 Phase 2
NCT01110499 Allergan Ocular Hypertension|Primary Open-Angle Glaucoma June 2010 Phase 2
NCT00332540 Allergan Ocular Hypertension August 2001 Phase 3
NCT00332059 Allergan Ocular Hypertension May 2003 Phase 3
NCT00332072 Allergan Ocular Hypertension August 2001 Phase 3
NCT02143843 ForSight Vision5, Inc. Primary Open-Angle Glaucoma|Ocular Hypertension May 2014 Phase 1|Phase 2
NCT01157364 Allergan Open-Angle Glaucoma|Ocular Hypertension August 2010 Phase 1|Phase 2
NCT01628601 Allergan Glaucoma, Open-Angle|Ocular Hypertension May 2010
NCT01999348 Allergan Glaucoma, Primary Open Angle|Ocular Hypertension November 2013
NCT02176356 Allergan Facial Rhytides|Crow's Feet Lines|Glabellar Lines|Nasolabial Fold June 2014 Phase 4
NCT01325337 Allergan Alopecia|Alopecia, Androgenetic|Baldness June 2011 Phase 2
NCT01325350 Allergan Alopecia|Baldness June 2011 Phase 2
NCT01253902 Allergan Glaucoma, Open-Angle|Ocular Hypertension December 2010 Phase 4
NCT02863705 Allergan Glaucoma, Open-Angle|Normal Tension Glaucoma July 5, 2016 Phase 4
NCT00273455 Pharmaceutical Research Network Open-Angle Glaucoma January 2006 Phase 4
NCT00809848 Allergan Ocular Hypertension|Glaucoma February 2009 Phase 1|Phase 2
NCT00539526 Allergan Open Angle Glaucoma|Ocular Hypertension September 2007 Phase 4
NCT01016691 Vistakon Pharmaceuticals Open-angle Glaucoma|Ocular Hypertension October 2009 Phase 2
NCT01241240 Allergan Glaucoma, Open-Angle|Ocular Hypertension March 2011 Phase 3
NCT01217606 Allergan Glaucoma, Open-Angle|Ocular Hypertension January 2011 Phase 3
NCT01978015 University of Campinas, Brazil Uveitis, Anterior|Cystoid Macular Edema October 2011 Phase 4
NCT00329095 Robin, Alan L., M.D. Glaucoma|Ocular Hypertension December 2005 Phase 4
NCT01655758 University of Parma Ocular Hypertension January 2002 Phase 4
NCT02390284 University of Miami|National Eye Institute (NEI) Glaucoma September 2014 Phase 3
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.4063 mL 12.0317 mL 24.0633 mL
5 mM 0.4813 mL 2.4063 mL 4.8127 mL
10 mM 0.2406 mL 1.2032 mL 2.4063 mL
References
Molecular Weight

415.57

Formula

C₂₅H₃₇NO₄

CAS No.

155206-00-1

Storage
Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bimatoprost
Cat. No.:
HY-B0191
Quantity: